Abstract A 90-year-old man presented with subcutaneous ecchymoses. He had been under treatment with dabigatran etexilate methanesulfonate (DEM). Prolonged APTT and decreased PT was developed 2 months after the start of DEM, more prolonged 6 months later. DEM was discontinued, the coagulopathy did not improve. Factor V activity was decreased, along with appearance of coagulation factor V inhibitor (FVI). He did not have antiphospholipid syndrome or malignancy. He was diagnosed as having acquired FVI caused by DEM. Steroid pulse therapy was effective. There have been 74 reported cases of AFVI induced by drug treatment, but none after treatment with DEM.
Introduction
Clinical symptoms of acquired factor V inhibitor (AFVI) are varied, ranging from asymptomatic to hemorrhage and thrombotic tendency [1] . Some of the consequences may be fatal [2] , underscoring the need for prompt diagnosis and treatment. In addition, various causes of AFVI have been reported, and approximately 30 % of cases are idiopathic [3] . To the best of our knowledge, there have been no reports of AFVI caused by treatment with dabigatran etexilate methanesulfonate (DEM). DEM was first approved for use in the field of orthopedic surgery for the primary prevention of venous thromboembolic events in Europe in March 2008. Thereafter, it was approved for use in the US in October 2010, in Japan in January 2011, and in Europe in August 2011, as an agent for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Thus, DEM is a relatively new drug. DEM suppresses the formation of fibrin from fibrinogen through direct and selective inhibition of thrombin activity, thereby exerting anticoagulant and antithrombotic effects [4] . Use of DEM is expected to increase in the future, because of its advantages, such as availability as a formulation for oral use and better controllability of blood coagulability than warfarin. Here, we report a patient who developed AFVI following treatment with this drug, in whom careful treatment was considered necessary. benidipine hydrochloride, furosemide, verapamil hydrochloride and aspirin for thoracic aortic aneurysm, aortic regurgitation (grade II), mitral regurgitation (grade I), hypertension and atrial fibrillation from a local hospital. Multiple cerebral microinfarctions developed, and his medication was changed from aspirin to DEM at 220 mg/ day in October 2012. At this time, his activated partial thromboplastin time (APTT) (33.7 s; reference value, 30.2 s) and prothrombin time (PT) (89.5 %; reference value 70-100 %) were within normal range. In early December 2012, the APTT became prolonged to 61.6 s, and the dose of DEM was reduced to 150 mg/day. In late December, the APTT was well controlled (49.3 s), and the drug was continued at the same dose. In early April 2013, DEM was discontinued because of marked prolongation of the APTT to 134.9 s and reduction of the PT to less than 20 %. Around this time, ecchymoses and eruptions appeared over the whole body. In mid-May, approximately a month and a half after the discontinuation of DEM, further decrease of the blood coagulability was noted (APTT, 140.2 s), and the patient was admitted to a local hospital.
At the time of admission to the local hospital, the patient had a body height of 151 cm and body weight of 65.4 kg, body temperature of 36.5°C, blood pressure of 150/90 mmHg, (irregular) pulse of 100/min, clear consciousness, no conjunctival pallor, no icterus, no hepatosplenomegaly, and no abnormal neurological findings. There were no palpable superficial lymph nodes. Eruptions and ecchymoses with itching were seen on the scalp, face, chest, abdomen, back, and the upper extremities of both sides.
The laboratory findings at the time of admission are shown in Table 1 .
His clinical course after admission is shown in Fig. 1 . Skin biopsy from the erythematous areas on the face and dorsum of the hand led to a diagnosis of DEM-induced photodermatitis. A drug lymphocyte stimulation test was negative for DEM. The patient was treated with oral antiallergic agents and topical steroids, however, his condition did not improve. In mid-May 2013, the patient's condition deteriorated further, with an APTT of 156.1 s and PT of less than 20 %. Measurement of the coagulation factor profile revealed markedly decreased factor V activity to B3 % (reference value 70-135 %) and somewhat reduced activities of factors II, VII, X and XI. There were no abnormal changes of any other coagulation factors. The test for coagulation factor V inhibitor was positive (4 Bethesda U/mL), while the tests for coagulation inhibitors of factors II, VII, X and XI, which showed reduced activities, were negative. The patient was unlikely to have antiphospholipid syndrome, because of the absence of thrombosis, negative test result for anticardiolipin IgG, and negative test result for anti-CLb2GP1 antibodies. Based on the above, he was diagnosed as having AFVI activity caused by DEM. In late May, the patient's condition deteriorated further, with an APTT of C180 s and PT of \20 %, and ecchymoses appeared over the whole body, being most pronounced on the abdominal wall. Therefore, steroid pulse therapy was administered, followed by continuation of treatment with prednisolone at a daily dose of 30 mg/day. In early June, the patient was referred to our department. At the time of referral, the test for coagulation factor V inhibitor was negative and the factor V activity had improved to 12 %. The bleeding tendency had also disappeared. In late June, the dose of prednisolone was gradually reduced to 20 mg/day. Because coagulation factor V inhibitor remained negative and the factor V activity and blood coagulability fell within normal range, treatment was started with warfarin. In early July, the patient was discharged and received outpatient treatment with prednisolone, the dose of which was gradually tapered to 5 mg/day. The clinical course remained favorable with negative coagulation factor V inhibitor activity and factor V activity within normal range. In addition, slight increases of the serum carcinoembryonic antigen (CEA) (23.3 ng/ mL) and squamous cell carcinoma-related antigen (SCC) In mid-May, he had developed a bleeding tendency. The coagulation factor V activity decreased again to B3 % and the test for coagulation factor V inhibitor activity was positive. The patient was diagnosed as having acquired factor V inhibitor (AFVI) induced by DEM. Steroid pulse therapy was administered, following which the coagulation factor V activity fell within normal range, the test for factor V inhibitor became negative. The patient was received treatment with prednisolone, which was gradually tapered in dose and finally discontinued. The AFVI has not recurred to date (4.6 ng/mL) were observed, however, whole-body contrast-enhanced CT revealed no malignancies. Upper and lower gastrointestinal endoscopic examinations revealed no abnormalities.
Discussion
Mild coagulopathy developed approximately 2 months after the start of treatment with DEM and had progressed until 6 months after the start of treatment. The blood coagulability did not improve even after discontinuation of the DEM, and the patient was found to have factor V inhibitor in the serum, which led to the diagnosis of AFVI activity caused by DEM. AFVI was first reported in 1955 [5] , and approximately 150 cases have been reported to date [3, [5] [6] [7] ; however, most of the case reports are only descriptive. AFVI is a rare condition, occurring at an incidence of 0.09/100,000 [3] to 0.29/1,000,000 [6] per year. However, a significant percentage are asymptomatic carriers [1] , and the actual incidence is speculated to be higher. The clinical symptoms of AFVI vary, ranging from asymptomatic to fatal hemorrhage and thrombotic tendency [1] ; the case fatality rate has been reported to be in the range of 14-31 % [2, 7] , underscoring the importance of prompt diagnosis and treatment.
One published report provides a summary of 74 case reports of AFVI with meaningful data [7] . Of these, 33 cases in which the AFVI was considered to be caused by drugs are listed in Table 2 . The patients were relatively old, with a mean age of 66.2 years, and AFVI was more common in men, with a male/female ratio of 24:9. All causative agents were antibiotics, with b-lactamases being the most commonly implicated causative agent (18 cases), followed by aminoglycosides (12 cases). The present patient was not treated with antibiotics, and DEM was strongly suspected as the causative agent. According to the aforementioned report, steroids (12 cases) and fresh frozen plasma (FFP) (17 cases) are the most common therapeutic agents for AFVI, followed by cyclophosphamide (CPA), intravenous injection of immunoglobulin (IVIG) and platelet transfusion; steroids were effective in the present patient. Of the 74 reported cases, 26 achieved remission in an average of 8.5 weeks, suggesting that the prognosis of AFVI is relatively good. However, 5 patients died (4 died of hemorrhage, and 1 died of unknown cause) and 2 patients had persistent factor V inhibitory in the serum, indicating the need for careful treatment.
The major causes of AFVI other than drugs include surgery, infections, malignancies, autoimmune diseases, and organ transplantation. Blood transfusion, fibrin preparations, bovine thrombin, etc., have also been reported as other causes of AFVI, but these were not used in the present patient. AFVI is idiopathic in 21 % [7] to 30 % [3] M/F male to female, AGS aminoglycoside, CPFX ciprofloxacin, CPS cephalosporin, CAF chloramphenicol, FFP fresh frozen plasma, CPA cyclophosphamide, IVIG intravenous injection of immunoglobulin, PLT platelet concentrates, VK vitamin K, AZT azathioprine, PCC prothrombin complex concentrates, CsA cyclosporine, AF antifirinolytic agents, CP cryoprecipitates, rFVIIa recombinant factor VII activated, RTX rituximab, PEX plasma exchange, SDFP solvent/detergent-treated frozen plasma, W week, M month of the cases. The pathogenic mechanism of AFVI due to DEM is unknown, but if coagulopathy is observed during treatment with DEM, it will be necessary to measure the factor V activity. No standard treatment for AFVI has been established, however, immunosuppressive agents such as steroids are highly effective [3, 7, 8] . There have been reports of patients with AFVI improving spontaneously without treatment [3, 7, 8] and treatment is not necessary for asymptomatic patients [9] . However, some patients have fatal hemorrhage [2, 3, 7] , and it is difficult to determine which patients may be indicated for treatment. The present patient showed markedly reduced blood coagulability, with an APTT of C180 s and PT of \20 %, and showed a bleeding tendency. Therefore, steroid pulse therapy was administered, and the patient's life was saved. In early June, the factor V inhibitor disappeared, factor V activity increased, the blood coagulability fell to within normal range, and the bleeding tendency also disappeared. Therefore, treatment with warfarin was initiated.
There have been 2 reported cases of AFVI after treatment with warfarin [2, 10] , and it is considered that careful follow-up with periodic measurement of not only the blood coagulability, but also the factor V activity and factor V inhibitor is necessary in the future.
There have been no reports of AFVI caused by DEM, and the underlying pathogenic mechanisms, clinical symptoms, treatment and prognosis are unknown. In the future, further analysis will be necessary on a larger number of cases.
In general, the prognosis of AFVI depends on the underlying disease inducing the AFVI [7, 11] , and it is important to screen the patients for malignancies [11] . In the present patient, a detailed whole-body examination revealed no malignancies. Prevention of fatal hemorrhage by early detection of AFVI and management of the underlying diseases are considered important for a better prognosis.
